Rifampin Injection Shortage: FDA Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Rifampin Injection is currently listed in shortage by the FDA, but both manufacturers report it as available, with advice to check wholesalers for inventory.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Rifampin Injection.
Rifampin Injection Shortage Update
As a professional health news writer for Areazine, I aim to provide clear and empathetic information about drug shortages. This article discusses the current shortage of Rifampin Injection, a medication that may be essential for some patients. We encourage readers to stay informed and consult healthcare professionals for personalized advice.
What's in Shortage
Rifampin Injection is the generic name for this drug, with the brand name RIFAMPIN. It is available in injection dosage form and falls under the therapeutic category of Anti-Infective. The shortage status is current, with the initial posting date of 02/17/2021 and last updated on 04/02/2026.
Which Manufacturers Are Affected
The following manufacturers are involved:
- Fresenius Kabi USA, LLC: Availability is reported as available. Related information includes checking wholesalers for inventory. The presentation is Rifampin, Injection, 600 mg (NDC 63323-351-20). Contact information: 888-386-1300.
- Mylan Institutional, a Viatris Company: Availability is reported as available. The presentation is Rifampin, Injection, 600 mg/10 mL (NDC 67457-445-60). Contact information: 800-796-9526.
Why There's a Shortage
No specific reason was given for the shortage.
What Patients Should Do
If you rely on Rifampin Injection, we recommend taking these practical steps: Speak with your pharmacist to check local availability and options. You may also contact the manufacturers directly using the provided information. Remember, patients should consult their healthcare provider for any guidance on their treatment—do not make changes without professional advice.
Source
This information is sourced from the FDA Drug Shortages Database, with the shortage initially posted on 02/17/2021 and last updated on 04/02/2026.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,831 characters here).
Similar severity timing
Same severity (low) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.